2021 Western China Smart Healthcare Industry Summit: An Unmissable Event for Medical Innovation in Chengdu
Looking back on the development of the global healthcare industry, every key milestone has been linked to major technological advancements.
What few people realize is that behind the breakthroughs in industrial development lies a region and ecosystem with advantages in industrial clustering and deep collaborative capabilities.For healthcare innovation enterprises, it is particularly crucial to identify regions and ecosystems that are conducive to their growth.
Thus, it is evident that numerous regions are investing various resources and hosting summits to attract and support the steady development of healthcare innovation projects. Amidst this wave of momentum driving innovative development,There is an industry summit that medical innovation projects cannot afford to miss.
Why?
Because, in terms of the caliber and quality of its organization, this summit delves deeper while also broadening its scope.
How should this be understood? This requires returning to the requirements of medical innovation projects.
In terms of depth, first, are there top-tier industry experts providing insights and perspectives? Second, are the topics sufficiently cutting-edge and focused? Third, is the organizer professional and authoritative enough?
In terms of breadth: First, are there multi-party resources available for assistance and collaboration? Second, are the activity formats diverse and engaging? Third, are there opportunities for business negotiations and project matchmaking?
The summit will meet all the aforementioned needs, and even deliver more surprises.
This summit, held on September 27–28, was jointly guided by the Chengdu Municipal Bureau of Economy and Information Technology, the Chengdu Municipal Bureau of Investment Promotion, the Chengdu Municipal Health Commission, and the Chengdu Municipal Healthcare Security Administration; hosted by the China Pharmaceutical Enterprise Management Association; organized by AstraZeneca Investment (China) Co., Ltd. and E-Pharma Manager; co-organized by the Administrative Committee of Chengdu High-Tech Industrial Development Zone; and supported through strategic partnerships by the Sichuan International Medical Exchange Promotion Association, the Chengdu Pharmaceutical and Health Industry Ecosystem Alliance, the Chengdu Healthcare Security Alliance, CICC Capital, Luye Pharma Group, Genetron Health, Chengdu Frontier Medical Center, MedVator, and Cyzone.“2021 Western Smart Healthcare Industry Summit”。
The summit will be held at the Frontier Medical Center in Chengdu High-Tech Zone, under the theme “Ecological Integration, Innovating for a Winning Future.” It will bring together multiple stakeholders—including government bodies, industry enterprises, academic institutions, research organizations, capital investors, and hospitals—to aggregate resources and achieve synchronized resonance and ecological development within the western China pharmaceutical ecosystem.
“What Sets the ‘2021 Western Smart Healthcare Industry Summit’ Apart?”
Specifically, in terms of depth, this summit has brought together senior industry figures. At the main forum, Tan Yong, Vice President of the China Pharmaceutical Enterprise Management Association, will serve as moderator. Keynote speeches will be delivered by Wang Lei, Global Executive Vice President and President of International Business and China at AstraZeneca; Wei Yuquan, Academician of the Chinese Academy of Sciences; Wang Mingwei, Director of the National Center for Drug Screening; and Shan Junbao, President of CICC Capital.
Furthermore, Li Weimin, President of West China Hospital; Li Ming, Director of the Chengdu High-Tech Zone Bureau of Biology; Li Jin, Chairman of Chengdu HitGen Inc.; Li Shaochun, General Manager of IBM Watson Health in Greater China; and Yang Dajun, Chairman and CEO of Ascentage Pharma, will engage in a “brainstorming” session on the integration of smart healthcare with industry.
In a discussion centered on how industrial convergence empowers a new ecosystem in the healthcare industry, Cao Guoxiong, Chairman of Puhua Group; Wang Sizhen, Co-founder and CEO of Genetron Health (Beijing) Technology Co., Ltd.; Liu Gexin, Chairman of Sichuan Kelun Pharmaceutical Co., Ltd.; Chen Bo, Chairman of Keymed Biosciences Inc. (Chengdu); Hong Hao, Chairman and CEO of Asymchem Laboratories (Tianjin) Co., Ltd.; and Wang Qinghan, Director and CEO of Chengdu Kanghua Biological Products Co., Ltd., will also engage in an exchange of ideas.
Furthermore, the topics are highly focused. At the main forum, industry leaders will center their sharing and discussions on key issues such as frontier areas in life sciences, development trends in the pharmaceutical industry, and the integration of smart healthcare innovation with ecosystem building, thereby helping attendees jointly seize opportunities in the future development of healthcare. In the parallel sessions, the focus will be on four themes: local innovation in biopharmaceuticals, opportunities under health insurance reform, innovation in traditional Chinese medicine (TCM), and the development of internet hospitals, with heavyweight guests from each respective sector invited to provide in-depth insights.
Next, let's look at the breadth.First, the event boasts extensive coverage. Both the main forum of the summit and its four parallel sessions bring together diverse stakeholders from government, industry, academia, research, healthcare, and investment sectors. It gathers relevant government departments, executives from more than 50 renowned domestic and international pharmaceutical companies, top-tier clinical translation institutions, industry-leading enterprises, and premier healthcare investors to share insights. Participants engage in in-depth discussions and dialogue on today’s most pressing topics, including policy interpretation, pharmaceutical innovation, industry development, and internet-based healthcare. The aim is to fully promote cross-sector exchange, knowledge sharing, and collaboration, thereby providing more comprehensive support and synergy for innovation in the healthcare industry.
Furthermore, the event featured a diverse range of formats. In addition to keynote speeches, the various forums at this summit included roundtable discussions and high-level dialogues. This approach not only ensured depth in content but also facilitated multi-party discussions on industry challenges, pain points, and potential solutions, thereby providing attendees with greater food for thought.
It is worth noting that on the evening of September 28, there will also be“Integrating Chinese and Western Medicine—Chengdu Unicorn Night”Here, AstraZeneca will announce its ecosystem collaborations, while attendees can identify high-quality partners with strong ecosystem fit and engage in face-to-face discussions on business opportunities and project matchmaking.
Furthermore, high-quality enterprises are better positioned to join the Chengdu International Life Science Innovation Park, a life science innovation incubation platform jointly established by AstraZeneca, a global leading biopharmaceutical company, in collaboration with the Chengdu Municipal Government and the Chengdu High-Tech Industrial Development Zone. By doing so, they can access professional services and support from a one-stop incubation and acceleration platform, including physical space, incentive policies, specialized services, mentorship programs, business acceleration, global expansion assistance, and capital support.
The core driver of the development of the medical industry is innovation, which often requires the support and collaboration of multiple resources.In other words, ecological integration is the foundation of medical innovation.
Thus, it is evident that Chengdu, as the host city of this summit, has devoted significant efforts in recent years to cultivating its biopharmaceutical industry ecosystem. These initiatives—including the introduction of major projects and talent, as well as incentives for companies to go public—have injected new momentum into the development of Chengdu’s biopharmaceutical sector.
As a national-level base for R&D and innovation in the biopharmaceutical industry, the National (Chengdu) Biopharmaceutical Industry Innovation Incubation Base, and the largest distribution and trade hub for biopharmaceuticals in central and western China, Chengdu’s pivotal role in the healthcare sector of western China is becoming increasingly prominent. To date, the Chengdu High-Tech Zone has attracted more than 3,000 pharmaceutical companies, along with the establishment of well-known medical institutions and major projects such as Luye Pharma’s production and R&D base for Xuezhikang.
Another example is AstraZeneca, the organizer, which is gradually transforming from a traditional pharmaceutical company into a platform-based enterprise. In response to the needs of whole-course patient management, it has established an innovation ecosystem integrating three key components: Innovation Centers, Innovation Industrial Parks, and Industry Funds. By closely aligning its service system with the core businesses of its partners, AstraZeneca is jointly creating a new, patient-centric innovative healthcare ecosystem.
It is evident that a new era centered on ecological integration and collaboration is rapidly approaching, with various stakeholders already taking proactive measures.We have good reason to believe that, in the current era of surging technological innovation, bringing together multiple stakeholders—including government, industry, academia, research institutions, healthcare providers, and investors—will accelerate communication and collaboration across the ecosystem, thereby providing sustained, robust momentum for the high-quality development of future healthcare.
Amidst the grand and immense opportunities shaping the future of healthcare, we invite you to join us in Chengdu from September 27 to 28 for this prestigious event.
